From bench-to-bedside in catastrophic cerebrovascular disease: Development of drugs targeting the endothelin axis in subarachnoid hemorrhage-related vasospasm

Neurological Research

Volumn 34, Issue 2, 2012, Pages 195-210

  Ardelt, A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Animal models; Cerebral vasospasm; Endothelin; Subarachnoid hemorrhage

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; 27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; 4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; BOSENTAN; CGS 26393; CGS 35066; CLAZOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; PERHYDRO 1 AZEPINYLCARBONYLLEUCYL DEXTRO TRYPTOPHYL DEXTRO TRYPTOPHAN; PHOSPHORAMIDON; PLACEBO; TAK 044; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

BRAIN ISCHEMIA; BRAIN VASOSPASM; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TARGETING; FLUSHING; HUMAN; HYPOTENSION; MOOD DISORDER; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SUBARACHNOID HEMORRHAGE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIOXANES; DRUG DISCOVERY; ENDOTHELINS; HUMANS; PYRIDINES; PYRIMIDINES; RECEPTORS, ENDOTHELIN; RECOVERY OF FUNCTION; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; VASOSPASM, INTRACRANIAL;

EID: 84857979616     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132811Y.0000000081     Document Type: Review

References (169)

1. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry 2007;78(12):1365-72.
2. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol 2009;8(4):355-69.
3. Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: population-based study and systematic review. Neurology 2010;74(19):1494-501.
4. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol 2009;8(7):635-42.
5. Rinkel GJ, Algra A. Long-term outcomes of patients with aneurysmal subarachnoid haemorrhage. Lancet Neurol 2011;10(4):349-56.
6. Al-Tamimi YZ, Orsi NM, Quinn AC, Homer-Vanniasinkam S, Ross SA. A review of delayed ischemic neurologic deficit following aneurysmal subarachnoid hemorrhage: historical overview, current treatment, and pathophysiology. World Neurosurg 2010;73(6):654-67.
7. Dorsch N. A clinical review of cerebral vasospasm and delayed ischaemia following aneurysm rupture. Acta Neurochir 2011;110(Pt 1):5-6.
8. Weyer GW, Nolan CP, Macdonald RL. Evidence-based cerebral vasospasm management. Neurosurg Focus 2006;21(3):E8.
9. Otten ML, Mocco J, Connolly ES, Jr, Solomon RA. A review of medical treatments of cerebral vasospasm. Neurol Res 2008;30(5):444-9.
10. Al-Tamimi YZ, Orsi NM, Quinn AC, Homer-Vanniasinkam S, Ross SA. A review of delayed ischemic neurologic deficit following aneurysmal subarachnoid hemorrhage: historical overview, current treatment, and pathophysiology. World Neurosurg 2010;73(6):654-67.
11. Deshaies EM, Boulos AS, Drazin D, Popp AJ. Evidence-based pharmacotherapy for cerebral vasospasm. Neurol Res 2009;31(6):615-20.
12. Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab 2011;31(6):1443-51.
13. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011;10(7):618-25.
14. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, doubleblind, placebo-controlled phase 2 dose-finding trial. Stroke 2008;39(11):3015-21.
15. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005;103(1):9-17.
16. Barth M, Capelle HH, Munch E, Thome C, Fiedler F, Schmiedek P, et al. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage-preliminary results from a randomized clinical series. Acta Neurochir (Wien) 2007;149(9):911-8; discussion 8.
17. Vergouwen MD. Effect of endothelin-receptor antagonists on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage remains unclear. Stroke 2009;40(12):e714.
18. Hansen-Schwartz J, Vajkoczy P, Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm: looking beyond vasoconstriction. Trends Pharmacol Sci 2007;28(6):252-6.
19. Pearl JD, Macdonald RL. Vasospasm after aneurysmal subarachnoid hemorrhage: need for further study. Acta Neurochir 2008;105:207-10.
20. Vergouwen MD. Vasospasm versus delayed cerebral ischemia as an outcome event in clinical trials and observational studies. Neurocrit Care 2011;15(2):308-11.
21. Vergouwen MD, Ilodigwe D, Macdonald RL. Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and-independent effects. Stroke 2011;42(4):924-9.
22. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59(3):467-77.
23. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40(6):2244-50.
24. STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30(12):2752-8.
25. Chow M, Dumont AS, Kassell NF. Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery 2002;51(6):1333-41; discussion 42.
26. Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999;353(9147):133-8.
27. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 2006;110(3):386-414.
28. Luscher TF, Wenzel RR. Endothelin and endothelin antagonists: pharmacology and clinical implications. Agents Actions 1995;45:237-53.
29. Ohlstein EH, Elliott JD, Feuerstein GZ, Ruffolo RR, Jr. Endothelin receptors: receptor classification, novel receptor antagonists, and potential therapeutic targets. Med Res Rev 1996;16(4):365-90.
30. Opgenorth TJ. Endothelin receptor antagonism. Adv Pharmacol 1995;33:1-65.
31. Watts SW. Endothelin receptors: what's new and what do we need to know? Am J Physiol 2009;298(2):R254-60.
32. Lin CL, Winardi W, Jeng AY, Kwan AL. Endothelinconverting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm. Neurol Res 2006;28(7):721-9.
33. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2z channels. J Hypertens Suppl 1988;6(4):S188-91.
34. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332(6163):411-5.
35. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86(8):2863-7.
36. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008;86(8):485-98.
37. Goldie RG. Endothelins in health and disease: an overview. Clin Exp Pharmacol Physiol 1999;26(2):145-8.
38. Iglarz M, Clozel M. At the heart of tissue: endothelin system and end-organ damage. Clin Sci (Lond) 2010;119(11):453-63.
39. Khimji AK, Rockey DC. Endothelin-biology and disease. Cell signal 2010;22(11):1615-25.
40. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46(3):325-415.
41. Matsumura Y, Ikegawa R, Tsukahara Y, Takaoka M, Morimoto S. Conversion of big endothelin-1 to endothelin-1 by two types of metalloproteinases derived from porcine aortic endothelial cells. FEBS Lett 1990;272(1-2):166-70.
42. Shigeno T, Mima T, Takakura K, Yanagisawa M, Saito A, Goto K, et al. Endothelin-1 acts in cerebral arteries from the adventitial but not from the luminal side. J Cardiovasc Pharmacol 1989;13 Suppl 5:S174-6.
43. Mima T, Yanagisawa M, Shigeno T, Saito A, Goto K, Takakura K, et al. Endothelin acts in feline and canine cerebral arteries from the adventitial side. Stroke 1989;20(11):1553-6.
44. Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovas Pharmacol 1998;32 Suppl 3:S2-13.
45. Salom JB, Torregrosa G, Alborch E. Endothelins and the cerebral circulation. Cerebrovasc Brain Metab Rev 1995;7(2):131-52.
46. Cardell LO, Uddman R, Edvinsson L. Endothelins: a role in cerebrovascular disease? Cephalalgia 1994;14(4):259-65.
47. Schinelli S. The brain endothelin system as potential target for brain-related pathologies. Current Drug Targets 2002;1(6): 543-53.
48. Schinelli S. Pharmacology and physiopathology of the brain endothelin system: an overview. Current Med Chem 2006; 13(6):627-38.
49. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. Faseb J 1995;9(12):1196-204.
50. Hansen-Schwartz J. Receptor changes in cerebral arteries after subarachnoid haemorrhage. Acta Neurol Scand 2004;109(1):33-44.
51. Loesch A. Localisation of endothelin-1 and its receptors in vascular tissue as seen at the electron microscopic level. Curr Vasc Pharmacol 2005;3(4):381-92.
52. Sugden PH. An overview of endothelin signaling in the cardiac myocyte. J Mol Cell Cardiol 2003;35(8):871-86.
53. Bourque SL, Davidge ST, Adams MA. The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol 2011;300:R1288-95.
54. Hirose H, Ide K, Sasaki T, Takahashi R, Kobayashi M, Ikemoto F, et al. The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog. Eur J Pharmacol 1995;277(1):77-87.
55. Ehrenreich H, Schilling L. New developments in the understanding of cerebral vasoregulation and vasospasm: the endothelin-nitric oxide network. Cleve Clin J Med 1995;62(2):105-16.
56. Haynes WG. Endothelins as regulators of vascular tone in man. Clin Sci (Lond) 1995;88(5):509-17.
57. Hansen-Schwartz J, Nordstrom CH, Edvinsson L. Human endothelin subtype A receptor enhancement during tissue culture via de novo transcription. Neurosurgery 2002; 50(1):127-33; discussion 33-5.
58. Hempelmann RG, Pradel RH, Barth HL, Mehdorn HM, Ziegler A. Interactions between vasoconstrictors in isolated human cerebral arteries. Acta Neurochir (Wien) 1997; 139(6):574-81; discussion 81-2.
59. Papadopoulos SM, Gilbert LL, Webb RC, D'Amato CJ. Characterization of contractile responses to endothelin in human cerebral arteries: implications for cerebral vasospasm. Neurosurgery 1990;26(5):810-5.
60. Pierre LN, Davenport AP. Autoradiographic study of endothelin receptors in human cerebral arteries. J Cardiovasc Pharmacol 1995;26 Suppl 3:S326-8.
61. Pierre LN, Davenport AP. Blockade and reversal of endothelin-induced constriction in pial arteries from human brain. Stroke 1999;30(3):638-43.
62. Yu JC, Pickard JD, Davenport AP. Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells. Br J Pharmacol 1995;116(5):2441-6.
63. Alafaci C, Salpietro FM, Iacopino DG, Edvinsson L, Tomasello F. Endothelin: an endothelium-derived vasoactive peptide and its possible role in the pathogenesis of cerebral vasospasm. Ital J Neurol Sci 1991;12(3 Suppl 11):55-8.
64. Ide K, Yamakawa K, Nakagomi T, Sasaki T, Saito I, Kurihara H, et al. The role of endothelin in the pathogenesis of vasospasm following subarachnoid haemorrhage. Neurol Res 1989;11(2):101-4.
65. Kobayashi H, Hayashi M, Kobayashi S, Kabuto M, Handa Y, Kawano H. Effect of endothelin on the canine basilar artery. Neurosurgery 1990;27(3):357-61.
66. Nishizawa S, Chen D, Yokoyama T, Yokota N, Otha S. Endothelin-1 initiates the development of vasospasm after subarachnoid haemorrhage through protein kinase C activation, but does not contribute to prolonged vasospasm. Acta Neurochir (Wien) 2000;142(12):1409-15.
67. Shigeno T, Mima T, Yanagisawa M, Saito A, Fujimori A, Shiba R, et al. Possible role of endothelin in the pathogenesis of cerebral vasospasm. J Cardiovasc Pharmacol 1991;17 Suppl 7:S480-3.
68. Asano T, Ikegaki I, Suzuki Y, Satoh S, Shibuya M. Endothelin and the production of cerebral vasospasm in dogs. Biochem Biophys Res Commun 1989;159(3):1345-51.
69. Willette RN, Sauermelch C, Ezekiel M, Feuerstein G, Ohlstein EH. Effect of endothelin on cortical microvascular perfusion in rats. Stroke 1990;21(3):451-8.
70. Willette RN, Sauermelch CF. Abluminal effects of endothelin in cerebral microvasculature assessed by laser-Doppler flowmetry. Am J Physiol 1990;259(6 Pt 2):H1688-93.
71. Kobayashi H, Hayashi M, Kobayashi S, Kabuto M, Handa Y, Kawano H, et al. Cerebral vasospasm and vasoconstriction caused by endothelin. Neurosurgery 1991;28(5):673-8; discussion 8-9.
72. Khurana VG, Besser M. Pathophysiological basis of cerebral vasospasm following aneurysmal subarachnoid haemorrhage. J Clin Neurosci 1997;4(2):122-31.
73. Kolias AG, Sen J, Belli A. Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches. J Neurosci Res 2009;87(1):1-11.
74. Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007;76(1):8-18.
75. Fuwa I, Mayberg M, Gadjusek C, Harada T, Luo Z. Enhanced secretion of endothelin by endothelial cells in response to hemoglobin. Neurol Med Chir (Tokyo) 1993;33(11):739-43.
76. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Ann Rev Physiol 1999;61:391-415.
77. Ohlstein EH, Storer BL. Oxyhemoglobin stimulation of endothelin production in cultured endothelial cells. J Neurosurg 1992;77(2):274-8.
78. Vatter H, Konczalla J, Seifert V. Endothelin related pathophysiology in cerebral vasospasm: what happens to the cerebral vessels? Acta Neurochir 2011;110(Pt 1):177-80.
79. Wang X, Zhu C, Zhang G, Lu Y. Changes of endothelin during cerebral vasospasm after experimental subarachnoid hemorrhage. Chin Med J 1995;108(8):586-90.
80. Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F, Hirakawa K. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet 1989;2(8676):1402.
81. Fujimori A, Yanagisawa M, Saito A, Goto K, Masaki T, Mima T, et al. Endothelin in plasma and cerebrospinal fluid of patients with subarachnoid haemorrhage. Lancet 1990;336(8715):633.
82. Kraus GE, Bucholz RD, Yoon KW, Knuepfer MM, Smith KR, Jr. Cerebrospinal fluid endothelin-1 and endothelin-3 levels in normal and neurosurgical patients: a clinical study and literature review. Surg Neurol 1991;35(1):20-9.
83. Suzuki H, Sato S, Suzuki Y, Oka M, Tsuchiya T, Iino I, et al. Endothelin immunoreactivity in cerebrospinal fluid of patients with subarachnoid haemorrhage. Ann Med 1990;22(4):233-6.
84. Suzuki H, Sato S, Suzuki Y, Takekoshi K, Ishihara N, Shimoda S. Increased endothelin concentration in CSF from patients with subarachnoid hemorrhage. Acta Neurol Scand 1990;81(6):553-4.
85. Yamaji T, Johshita H, Ishibashi M, Takaku F, Ohno H, Suzuki N, et al. Endothelin family in human plasma and cerebrospinal fluid. The J Clin Endocrinol Metab 1990;71(6):1611-5.
86. Suzuki R, Masaoka H, Hirata Y, Marumo F, Isotani E, Hirakawa K. The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1992;77(1):96-100.
87. Hamann G, Isenberg E, Strittmatter M, Schimrigk K. Absence of elevation of big endothelin in subarachnoid hemorrhage. Stroke 1993;24(3):383-6.
88. Gaetani P, Rodriguez Y, Baena R, Grignani G, Spanu G, Pacchiarini L, Paoletti P. Endothelin and aneurysmal subarachnoid haemorrhage: a study of subarachnoid cisternal cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1994;57(1):66-72.
89. Kobayashi H, Ide H, Ishii H, Kabuto M, Handa Y, Kubota T. Endothelin-1 levels in plasma and cerebrospinal fluidfollowing subarachnoid haemorrhage. J Clin Neurosci 1995;2(3):252-6.
90. Seifert V, Loffler BM, Zimmermann M, Roux S, Stolke D. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg 1995;82(1):55-62.
91. Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schütt S, et al. Endothelin-1 in subarachnoid hemorrhage: an acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke 2000;31(12):2971-5.
92. Suzuki K, Meguro K, Sakurai T, Saitoh Y, Takeuchi S, Nose T. Endothelin-1 concentration increases in the cerebrospinal fluid in cerebral vasospasm caused by subarachnoid hemorrhage. Surg Neurol 2000;53(2):131-5.
93. Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 2000;92(3):390-400.
94. Mascia L, Fedorko L, Stewart DJ, Mohamed F, terBrugge K, Ranieri VM, et al. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke 2001; 32(5):1185-90.
95. Menon DK, Day D, Kuc RE, Downie AJ, Chatfield DA, Davenport AP. Arteriojugular endothelin-1 gradients in aneurysmal subarachnoid haemorrhage. Clin Sci (Lond) 2002;103 Suppl 48:399S-403S.
96. Juvela S. Plasma endothelin and big endothelin concentrations and serum endothelin-converting enzyme activity following aneurysmal subarachnoid hemorrhage. J Neurosurg 2002; 97(6):1287-93.
97. Kessler IM, Pacheco YG, Lozzi SP, de Araujo AS, Jr, Onishi FJ, de Mello PA. Endothelin-1 levels in plasma and cerebrospinal fluid of patients with cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol 2005;64 Suppl 1:S1:2-5; discussion S1:5.
98. Kastner S, Oertel MF, Scharbrodt W, Krause M, Boker DK, Deinsberger W. Endothelin-1 in plasma, cisternal CSF and microdialysate following aneurysmal SAH. Acta Neurochir (Wien) 2005;147(12):1271-9; discussion 9.
99. Gruber A, Roessler K, Georgopoulos A, Missbichler A, Bonelli R, Richling B. Evaluation of big endothelin-1 concentrations in serum and ventricular cerebrospinal fluid after early surgical compared with nonsurgical management of ruptured intracranial aneurysms. Neurosurg Focus 2000; 8(5):e6.
100. Shirakami G, Magaribuchi T, Shingu K, Kim S, Saito Y, Nakao K, et al. Changes of endothelin concentration in cerebrospinal fluid and plasma of patients with aneurysmal subarachnoid hemorrhage. Acta Anaesthesiol Scand 1994;38(5):457-61.
101. Vatter H, Mursch K, Zimmermann M, Zilliken P, Kolenda H, Seifert V, et al. Endothelin-converting enzyme activity in human cerebral circulation. Neurosurgery 2002;51(2):445-51; discussion 51-2.
102. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, et al. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 1989;2(8653):53-4.
103. Ziv I, Fleminger G, Djaldetti R, Achiron A, Melamed E, Sokolovsky M. Increased plasma endothelin-1 in acute ischemic stroke. Stroke 1992;23(7):1014-6.
104. Zimmermann M, Seifert V. Endothelin and subarachnoid hemorrhage: an overview. Neurosurgery 1998;43(4):863-75; discussion 75-6.
105. Pluta RM, Boock RJ, Afshar JK, Clouse K, Bacic M, Ehrenreich H, et al. Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg 1997;87(2):287-93.
106. Zimmermann M. Endothelin in cerebral vasospasm. Clinical and experimental results. J Neurosurg Sci 1997;41(2):139-51.
107. Thampatty BP, Sherwood PR, Gallek MJ, Crago EA, Ren D, Hricik AJ, et al. Role of endothelin-1 in human aneurysmal subarachnoid hemorrhage: associations with vasospasm and delayed cerebral ischemia. Neurocrit Care 2011;15(1):19-27.
108. Ostrow LW, Sachs F. Mechanosensation and endothelin in astrocytes-hypothetical roles in CNS pathophysiology. Brain Res 2005;48(3):488-508.
109. Leppaluoto J, Ruskoaho H. Endothelin peptides: biological activities, cellular signalling and clinical significance. Ann Med 1992;24(3):153-61.
110. Konczalla J, Vatter H, Weidauer S, Raabe A, Seifert V. Alteration of the cerebrovascular function of endothelin B receptor after subarachnoidal hemorrhage in the rat. Exp Biol Med (Maywood) 2006;231(6):1064-8.
111. Vatter H, Konczalla J, Weidauer S, Preibisch C, Raabe A, Zimmermann M, et al. Characterization of the endothelin-B receptor expression and vasomotor function during experimental cerebral vasospasm. Neurosurgery 2007;60(6):1100-8; discussion 8-9.
112. Hansen-Schwartz J, Ansar S, Edvinsson L. Cerebral vasoconstriction after subarachnoid hemorrhage-role of changes in vascular receptor phenotype. Front Biosci 2008;13:2160-4.
113. Alafaci C, Jansen I, Arbab MA, Shiokawa Y, Svendgaard NA, Edvinsson L. Enhanced vasoconstrictor effect of endothelin in cerebral arteries from rats with subarachnoid haemorrhage. Acta Physiol Scand 1990;138(3):317-9.
114. Roux S, Loffler BM, Gray GA, Sprecher U, Clozel M, Clozel JP. The role of endothelin in experimental cerebral vasospasm. Neurosurgery 1995;37(1):78-85; discussion 85-6.
115. Hino A, Tokuyama Y, Kobayashi M, Yano M, Weir B, Takeda J, et al. Increased expression of endothelin B receptor mRNA following subarachnoid hemorrhage in monkeys. J Cereb Blood Flow Metab 1996;16(4):688-97.
116. Hansen-Schwartz J, Szok D, Edvinsson L. Expression of ET(A) and ET(B) receptor mRNA in human cerebral arteries. Br J Neurosurg 2002;16(2):149-53.
117. Lin CL, Jeng AY, Howng SL, Kwan AL. Endothelin and subarachnoid hemorrhage-induced cerebral vasospasm: pathogenesis and treatment. Curr Med Chem 2004;11(13): 1779-91.
118. Megyesi JF, Vollrath B, Cook DA, Findlay JM. In vivo animal models of cerebral vasospasm: a review. Neurosurgery 2000;46(2):448-60; discussion 60-1.
119. Matsumura Y, Ikegawa R, Suzuki Y, Takaoka M, Uchida T, Kido H, et al. Phosphoramidon prevents cerebral vasospasm following subarachnoid hemorrhage in dogs: the relationship to endothelin-1 levels in the cerebrospinal fluid. Life Sci 1991;49(11):841-8.
120. Caner HH, Kwan AL, Arthur A, Jeng AY, Lappe RW, Kassell NF, et al. Systemic administration of an inhibitor of endothelin-converting enzyme for attenuation of cerebral vasospasm following experimental subarachnoid hemorrhage. J Neurosurg 1996;85(5):917-22.
121. Kwan AL, Bavbek M, Jeng AY, Maniara W, Toyoda T, Lappe RW, et al. Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhibitor, CGS 26303, in an experimental model of subarachnoid hemorrhage. J Neurosurg 1997;87(2):281-6.
122. Kwan AL, Lin CL, Chang CZ, Wu HJ, Hwong SL, Jeng AY, et al. Continuous intravenous infusion of CGS 26303, an endothelin-converting enzyme inhibitor, prevents and reverses cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 2001;49(2):422-7; discussion 7-9.
123. Kwan AL, Lin CL, Chang CZ, Winardi D, Yen CP, Wu SC, et al. Oral administration of an inhibitor of endothelinconverting enzyme attenuates cerebral vasospasm following experimental subarachnoid haemorrhage in rabbits. Clin Sci (Lond) 2002;103 Suppl 48:414S-7S.
124. Kwan AL, Lin CL, Chang CZ, Wu SC, Howng SL, Jeng AY. Attenuation of SAH-induced cerebral vasospasm by a selective ECE inhibitor. Neuroreport 2002;13(2):197-9.
125. Vatter H, Zimmermann M, Seifert V, Schilling L. Experimental approaches to evaluate endothelin-A receptor antagonists. Methods Find Exp Clin Pharmacol 2004; 26(4):277-86.
126. Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 1992;50(4):247-55.
127. Clozel M, Watanabe H. BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci 1993;52(9):825-34.
128. Cosentino F, McMahon EG, Carter JS, Katusic ZS. Effect of endothelinA-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm. J Cardiovasc Pharmacol 1993;22 Suppl 8:S332-5.
129. Itoh S, Sasaki T, Asai A, Kuchino Y. Prevention of delayed vasospasm by an endothelin ETA receptor antagonist, BQ-123: change of ETA receptor mRNA expression in a canine subarachnoid hemorrhage model. J Neurosurg 1994; 81(5):759-64.
130. Hino A, Weir BK, Macdonald RL, Thisted RA, Kim CJ, Johns LM. Prospective, randomized, double-blind trial of BQ-123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys. J Neurosurg 1995;83(3):503-9.
131. Kim CJ, Bassiouny M, Macdonald RL, Weir B, Johns LM. Effect of BQ-123 and tissue plasminogen activator on vasospasm after subarachnoid hemorrhage in monkeys. Stroke 1996;27(9):1629-33.
132. Itoh S, Sasaki T, Ide K, Ishikawa K, Nishikibe M, Yano M. A novel endothelin ETA receptor antagonist, BQ-485, and its preventive effect on experimental cerebral vasospasm in dogs. Biochem Biophys Res Commun 1993;195(2):969-75.
133. Clozel M, Breu V, Gray GA, Kalina B, Löffler BM, Burri K, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994;270(1):228-35.
134. Clozel M, Breu V, Burri K, Cassal JM, Fischli W, Gray GA, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993;365(6448):759-61.
135. Breu V, Loffler BM, Clozel M. In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. FEBS Lett 1993;334(2):210-4.
136. Clozel M, Breu V, Gray GA, Loffler BM. In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol 1993;22 Suppl 8:S377-9.
137. Loffler BM, Breu V, Clozel M. Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett 1993;333(1-2):108-10.
138. Shigeno T, Clozel M, Sakai S, Saito A, Goto K. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurg 1995;37(1):87-90; discussion 90-1.
139. Zimmermann M, Seifert V, Loffler BM, Stolke D, Stenzel W. Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist. Neurosurgery 1996; 38(1):115-20.
140. Zuccarello M, Soattin GB, Lewis AI, Breu V, Hallak H, Rapoport RM. Prevention of subarachnoid hemorrhageinduced cerebral vasospasm by oral administration of endothelin receptor antagonists. J Neurosurg 1996;84(3):503-7.
141. Wallnofer A, Grosset D, Ohman J, Zubkov Y, Mendelow A, Jones R, et al. Effects of the endothelin antagonist bosentan in patients with elevated Doppler velocities after aneurysmal SAH. Proceedings of the 6th International Conference on Cerebral Vasospasm 1997;Session 16:99-100.
142. Nogueira RG, Bodock MJ, Koroshetz WJ, Topcuoglu MA, Carter BS, Ogilvy CS, et al. High-dose bosentan in the prevention and treatment of subarachnoid hemorrhageinduced cerebral vasospasm: an open-label feasibility study. Neurocrit Care 2007;7(3):194-202.
143. Prakash A, Perry CM. Bosentan. Am J Cardiovasc Drugs 2002;2(5):335-43; discussion 43
144. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997;283(3):1110-8.
145. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Schilling L, Seifert V. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: inhibitory effect on endothelin(A) receptor-mediated contraction. J Neurosurg 2005;102(6):1101-7.
146. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Seifert V, Schilling L. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: effect on endothelin(B) receptor-mediated relaxation. J Neurosurg 2005;102(6):1108-14.
147. Schubert GA, Schilling L, Thome C. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats. J Neurosurg 2008;109(6):1134-40.
148. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM. Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/ Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg 2000;93(6):992-7.
149. Sato S, Yonetani Y, Fujimoto M, Kita T, Kubo K, Nakashima T. Effects of an endothelin ET(A)-receptor antagonist, S-0139, on cerebral vasospasm and behavioral changes in dogs intracisternally administered endothelin-1. Life Sci 1998;62(13):PL191-7.
150. Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab 2011;31(6):1443-51.
151. Wartenberg KE, Mayer SA. Medical complications after subarachnoid hemorrhage: new strategies for prevention and management. Curr Opin Crit Care 2006;12(2):78-84.
152. Wartenberg KE, Schmidt JM, Claassen J, Temes RE, Frontera JA, Ostapkovich N, et al. Impact of medical complications on outcome after subarachnoid hemorrhage. Crit Care Med 2006;34(3):617-23; quiz 624.
153. Brunner F, Bras-Silva C, Cerdeira AS, Leite-Moreira AF. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 2006;111(2):508-31.
154. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Ann Rev Pharmacol Toxicol 2001;41:851-76.
155. Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Nature Rev 2002;1(12):986-1001.
156. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocrit Care 2011;13(3):416-24.
157. Pluta RM, Hansen-Schwartz J, Dreier J, Vajkoczy P, Macdonald RL, Nishizawa S, et al. Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought. Neurol Res 2009;31(2):151-8.
158. Schubert GA, Seiz M, Hegewald AA, Manville J, Thome C. Hypoperfusion in the acute phase of subarachnoid hemorrhage. Acta Neurochir 2011;110(Pt 1):35-8.
159. Hasegawa Y, Suzuki H, Sozen T, Altay O, Zhang JH. Apoptotic mechanisms for neuronal cells in early brain injury after subarachnoid hemorrhage. Acta Neurochir 2011;110(Pt 1):43-8.
160. Sabri M, Ai J, Macdonald RL. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan. Stroke 2011;42(5):1454-60.
161. Sehba FA, Pluta RM, Zhang JH. Metamorphosis of subarachnoid hemorrhage research: from delayed vasospasm to early brain injury. Mol Neurobiol 2011;43(1):27-40.
162. Sehba FA, Friedrich V. Early micro vascular changes after subarachnoid hemorrhage. Acta Neurochir 2011;110(Pt 1):49-55.
163. Chen G, Tariq A, Ai J, Sabri M, Jeon HJ, Tang EJ, et al. Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats. Brain Res 2011;1392:132-9.
164. Feng H, Mao Y, Zhang JH, editors. Early brain injury or cerebral vasospasm. Acta Neurochir Suppl 2011;110(1).
165. Jeon H, Ai J, Sabri M, Tariq A, Shang X, Chen G, et al. Neurological and neurobehavioral assessment of experimental subarachnoid hemorrhage. BMC Neurosci 2009;10:103.
166. Marbacher S, Sherif C, Neuschmelting V, Schläppi JA, Takala J, Jakob S, et al. Preliminary results of an ICP-controlled subarachnoid hemorrhage rabbit model for the study of delayed cerebral vasospasm. Acta Neurochir 2011;110(Pt 1):163-5.
167. Fisher M, Henninger N. Translational research in stroke: taking advances in the pathophysiology and treatment of stroke from the experimental setting to clinical trials. Curr Neurol Neurosci Rep 2007;7(1):35-41.
168. DeGraba TJ, Petttigrew LC. Why do neuroprotective drugs work in animals but not in humans? Neurol Clin 2000;18(2):475-93.
169. Tymianski M. Can molecular and cellular neuroprotection be translated into therapies for patients? Yes, but not the way we tried it before. Stroke 2010;41:S87-90.